Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2023-06-05 Director's Dealing
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
Director's Dealing 2023
Director's Dealing
2023-06-05 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 1, 2023, reporting changes in the company's board of directors and senior management. It details the appointment of a new CEO, CFO, and Chairman of the Board, along with biographical information and severance arrangements for outgoing executives. The content focuses on management changes rather than financial results, audit information, or other report types. Therefore, this document fits the category of Board/Management Information (MANG). The document length is sufficient and contains detailed information about management changes, not just an announcement or a brief note, confirming the classification.
2023-06-05 English
RW
Regulatory Filings Classification · 100% confidence The document is a formal letter addressed to the SEC requesting withdrawal of a Registration Statement on Form S-1. It references the Securities Act of 1933 and details the withdrawal of a registration statement related to a public offering that will not be pursued. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory communication about a capital market filing withdrawal, not a financial report or announcement of results. It is not a report publication announcement since it is not announcing a report release but a withdrawal request. This fits the category of a Regulatory Filing (RNS) as it is a compliance-related filing that does not fit other specific categories.
2023-06-02 English
S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A Registration Statement Amendment No. 5 filed with the SEC by Chemomab Therapeutics Ltd. It is a preliminary prospectus for an offering of American Depositary Shares and Pre-Funded Warrants. The document includes detailed information about the offering, company overview, risk factors, use of proceeds, capitalization, dilution, dividend policy, management discussion and analysis, executive compensation, security ownership, description of share capital and securities offered, underwriting, legal matters, and other related disclosures. This type of filing is a registration statement for securities offering under the Securities Act of 1933, which is distinct from annual reports, earnings releases, or other financial reports. It is not an announcement or a brief summary but a comprehensive registration document for a capital raising event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-05-19 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2023, reporting the issuance of a press release announcing financial results for the first quarter ended March 31, 2023. The text states that the press release is furnished as an exhibit and incorporated by reference, but the document itself does not contain detailed financial statements or substantive financial data. The length is 3943 characters, which is relatively short and consistent with a current report rather than a full financial report. The document is primarily an announcement of the earnings release, not the earnings release itself. Therefore, it should be classified as an Earnings Release (ER) since it announces quarterly financial results, but the actual detailed financial data is in the press release exhibit, which is typical for an ER filing in Form 8-K.
2023-05-11 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-11 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.